Cervical cancer is one of the most common malignant
tumors in
women worldwide. Locally advanced
cervical cancer is mainly treated with
radiotherapy and
chemotherapy, but there are problems such as high
recurrence rate and low
survival rate.
Bevacizumab, an
angiogenic inhibitor that acts on
vascular endothelial growth factor (
VEGF), has been recommended by the National Comprehensive
Cancer Network (NCCN) guidelines for the first-line
treatment of recurrent / metastatic advanced
cervical cancer in 2013. In recent years, the development of new targeted
drugs for
angiogenesis inhibitors, such as
endostatin, has further optimized the new targeted
therapy strategy for
patients with locally advanced and advanced
cervical cancer. Recombinant
human endostatin (endostar) is a novel anti-
angiogenesis drug independently developed by
Chinese scientists. Although it has been applied in the
treatment of
cervical cancer, it
needs to be further confirmed by high level evidence based medical evidence whether it can become a new option for targeted
treatment of
cervical cancer. In this article, clinical
research progress on the
treatment of
cervical cancer by endostar combined with
radiotherapy and / or
chemotherapy was reviewed, aiming to provide reference for the
optimization of
cervical cancer treatment strategy.